Vancouver, British Columbia, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - Doubleview Gold Corp. (TSXV: DBG) (OTCQB: DBLVF) (FSE: 1D4) ("Doubleview" or the "Company") is pleased to report assay results that extend Hat's gold-copper mineralization approximately 150m beyond the known resource envelope, opening a new exploration frontier the Company calls the Far East Zone. Drill holes H102-H108, completed during the Company's 2025 drill program at its 100%-owned Hat Project in northwestern British Columbia, also returned standout gold-enriched intervals including 8.0m grading 4.04 g/t Au and 112.0m grading 0.40 g/t Au.The 2025 drill program tested two distinct eastern areas of the Hat system, 233m apart. Holes H102-H105 add drill density and continuity data within and below the eastern side of the 2026 Preliminary Economic Assessment (PEA) pit shell, reinforcing the geological interpretation that underpins the Company's existing resource. Holes H106-H108 delivered the headline result: a new mineralized corridor, the Far East Zone, identified approximately 150m east of the current resource envelope, with elevated gold grades pointing toward a distinct and compelling geological target for future drilling.Drill holes H102-H108 were not completed in time to be incorporated into the Mineral Resource Estimate (MRE) with an effective date of February 4, 2026 or the PEA disclosed in March 2026. These assays do not constitute an updated MRE, mineral reserve estimate, pit optimization or economic analysis. The Company expects to evaluate the results in future mineral resource modelling and future engineering studies.CEO CommentFarshad Shirvani, President and CEO of Doubleview Gold Corp., commented: "These results demonstrate that the Hat Project continues to grow beyond the mineralized footprint used in our recently completed Mineral Resource Estimate and Preliminary Economic Assessment. The discovery of the Far East Zone approximately 150 metres beyond the current mineralization envelope, together with multiple broad mineralized intervals and significant gold enrichment, reinforces our belief that Hat remains substantially underexplored. Importantly, none of these holes were included in the February 2026 Mineral Resource Estimate or March 2026 PEA. We believe these results further highlight the scale potential of the Hat Project and provide compelling targets for future resource growth and engineering studies."HighlightsFar East Zone step-out: H106-H108 identify assay-supported mineralization approximately 150m east of the existing mineralization envelope. Follow-up drilling is required to determine geometry, continuity and extent.Two eastern data areas: the H102-H105 and H106-H108 platforms are approximately 233m apart. Figures 1 to 4 illustrate the separation between the East Zone and the Far East Zone.Gold-enriched intervals: H106-H108 show a higher gold contribution in several intervals, including 8.0m grading 4.04 g/t Au in H106 and 112.0m grading 0.40 g/t Au in H108.Resource confidence work: H102-H105 provide added drill density and continuity information for future geological modelling. The assays support future assessment of mineral resource classification. They do not, by themselves, establish a change in Measured, Indicated or Inferred mineral resource quantities or classifications.CuEq values exclude scandium oxide: reported Sc2O3 grades remain outside the CuEq calculation and are shown separately in Table 1.Selected Assay ResultsH102: 693.0m grading 0.20% CuEq,including 17.5m grading 1.25% CuEq.H103: 531.0m grading 0.20% CuEq,including 145.0m grading 0.40% CuEq and 26.1m grading 0.96% CuEq.H104: 259.0m grading 0.39% CuEq,including 142.0m grading 0.47% CuEq and23.0m grading 1.22% CuEq.H105: 427.1m grading 0.21% CuEq,including 71.2m grading 0.35% CuEq.H106: 444.0m grading 0.29% CuEq andan overlapping interval of 403.0m grading 0.31% CuEq,including 132.0m grading 0.51% CuEq,48.0m grading 1.00% CuEq,16.6m grading 2.02% CuEq and8.0m grading 3.93% CuEq.H107: 530.2m grading 0.20% CuEq andan overlapping interval of 463.0m grading 0.21% CuEq,including 22.2m grading 0.57% CuEq.H108: 135.0m grading 0.39% CuEq,including 112.0m grading 0.43% CuEq, anda separate interval of 75.0m grading 0.25% CuEq.All reported intervals are drill core lengths. True widths have not been determined. Complete assay intervals are presented in Table 1.Table 1: Summary of H102-H108 Drill Core Assay InterceptsDDHNoteFrom (m)To (m)Length (m)CuEq (%) not incl Sc2O3Au (g/t)Cu (%)Ag (g/t)Co (g/t)Sc2O3 (g/t)H102 6.0699.0693.00.200.090.100.145449.7H102incl.246.0699.0453.00.230.100.120.165554.1H102incl.252.0257.05.00.830.370.430.4120128.4H102incl.348.0696.0348.00.250.110.130.194753.9H102incl.348.0394.046.00.350.130.200.197862.1H102incl.527.0528.01.05.462.253.3011.0029228.5H102incl.681.5699.017.51.250.670.640.696044.1H103 9.0540.0531.00.200.100.090.156739.8H103incl.39.0119.080.00.290.200.090.305538.1H103incl.236.3532.0295.70.240.110.110.138140.9H103incl.387.0532.0145.00.400.190.200.218542.1H103incl.396.0540.0144.00.400.190.200.207842.2H103incl.399.0489.090.00.500.270.240.248146.2H103incl.406.5432.626.10.960.630.380.2510051H104 12.051.039.00.220.140.080.274737.3H104 425.0684.0259.00.390.160.230.316044H104incl.426.0568.0142.00.470.190.280.337338.9H104incl.460.0483.023.01.220.450.780.7611443.6H105 18.0445.1427.10.210.110.090.155647.3H105incl.187.0388.6201.60.260.110.140.166754.6H105incl.197.0268.271.20.350.160.180.258445.4H105incl.360.0388.628.60.450.220.240.165253.1H106 18.0462.0444.00.290.190.100.125342H106incl.105.0508.0403.00.310.200.120.135643.1H106incl.105.0372.0267.00.350.260.100.136240.4H106incl.105.0237.0132.00.510.450.090.165637.4H106incl.105.0153.048.01.000.980.120.296432.5H106incl.105.0121.616.62.022.050.190.487532.7H106incl.105.0113.08.03.934.040.340.8912427.4H107 6.8537.0530.20.200.100.090.125440.1H107incl.107.0570.0463.00.210.100.100.125941.2H107incl.107.0537.0430.00.230.110.110.126040.7H107incl.107.0167.060.00.350.310.060.115038.6H107incl.107.0129.222.20.570.540.080.175336.3H107incl.299.0528.0229.00.250.090.160.166442.7H107incl.299.0354.055.00.410.130.260.279547.5H107incl.471.0528.057.00.390.130.250.255949.7H108 15.0150.0135.00.390.350.060.204037.1H108incl.38.0150.0112.00.430.400.070.224238.2H108And501.0576.075.00.250.100.130.256236.9 Notes: 1 - Copper Equivalent (CuEq) currently does not include Scandium2 - The intervals presented in this table are not true widths. The true width of mineralized sections has not been determined.3 - Metal equivalents should not be relied upon for future evaluations. Drill hole intercepts included in this news release are core lengths that may or may not represent true widths of mineralization. It is not possible to determine true widths.4 - Parameters used to calculate Copper Equivalent: Au price (US$/oz): 2365.09; Ag price (US$/oz): 27.43; Cu price (US$/lb): 4.17; Co price (US$/lb): 14.76. Au recovery: 89.0%; Ag recovery: 68.0%; Cu recovery: 84.0%; Co recovery: 78.0%. * Copper Equivalent Calculation CuEq in % = ([Ag grade in ppm] *27.43*0.68/31.1035 + [Au grade in ppm] *2365.09*.89/31.1035 + 0.0001* [Co grade in ppm] *14.76*0.78*22.0462 + 0.0001* [Cu grade in ppm] *4.17*0.84*22.0462)/(4.17*22.0462*0.84).Details of the algorithm used to estimate %CuEq are presented in the notes above. The metal values used in our current algorithm are average trailing three years commodity prices, and do not reflect recent dramatic increases in prices of mineral commodities. Scandium, a high value strategic alloy metal (customarily quoted as Sc2O3 ) that is present in small but highly important amounts in Hat mineralization.Core samples are delivered securely to a fully accredited commercial laboratory and processed by industry-standard methods. Assays are received at irregular intervals, verified by reference to notes provided by our field crew, added to our database, and disseminated publicly by News Release.Figure 1: Plan view showing drill holes H102-H108 relative to the 2026 PEA pit shell and the eastern side of the Hat mineralized system.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_001full.jpgFigure 2: Cross-section through H102-H105 showing mineralized intervals within and below the eastern side of the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_002full.jpgFigure 3: Cross-section through H106-H108 showing the Far East Zone. The section illustrates a mineralized horizon extending more than 250m vertically in this view.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_003full.jpgGeological InterpretationResults from H102-H105 provide additional information on continuity within and below the eastern side of the PEA pit shell. Figure 2 shows reported intervals extending more than 150m below the shell in this section. The new data increase drill coverage in areas relevant to future resource modelling and future assessment of mineral resource classification.Results from H106-H108 identify the Far East Zone approximately 150m east of the existing mineralization envelope. The H106-H108 platform lies approximately 233m from the H102-H105 platform. Figure 3 illustrates the vertical extent of reported mineralization in the Far East Zone section. Additional drilling is required to determine the zone geometry, continuity and relationship to the broader Hat system.H106-H108 are also notable for gold-enriched intervals. H106 returned 48.0m grading 0.98 g/t Au, including 16.6m grading 2.05 g/t Au and 8.0m grading 4.04 g/t Au. H108 returned 112.0m grading 0.40 g/t Au. These results provide geological vectors for follow-up work. The significance of the metal distribution will be assessed through further drilling and modelling.Figure 4: Plan view of the 2026 PEA pit shell showing the East Zone and Far East Zone drill areas.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_004full.jpgFigure 5: Three-dimensional perspective view looking west showing the 2026 PEA pit shell and the eastern 2025 drill areas.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_005full.jpgFigure 6: Three-dimensional view looking west showing 2025 drill intercepts below the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_006full.jpgFigure 7: Three-dimensional view looking north showing eastern drill intercepts relative to the 2026 PEA pit shell.To view an enhanced version of this graphic, please visit:https://images.newsfilecorp.com/files/8003/300676_a6fe9797549ab975_007full.jpgTable 2 summarizes coordinates of the recent drill holes.Table 2: Drill Hole Locations and OrientationsCoordinates are reported in NAD83 / UTM Zone 9N.DDH ID UTM-East (m)UTM-North (m)Elevation (m)Dip (°)Azimuth (°)Max-Depth (m)H1023482036453897972-88.470732H1033482036453897972-67.84135720H1043482036453897972-75.79167702H1053482036453897972-80.7230663H1063484186453987982-89.110651H1073484186453987982-75.51100651H1083484186453987982-75.06170648 Quality Assurance and Quality Control:Hat Project drill cores are processed at Doubleview's field camp where they are photographed, measured and logged by our technical staff and then divided using a diamond bladed saw. One half is placed in a stout bag to form the assay sample that is forwarded securely to the independent analytical lab. The remaining half core is stored on site where it is available for further examination and sampling. The assay cores are subject to a Chain of Custody routine as they are shipped from camp to a bonded carrier for delivery to the lab.All core samples are prepared and analyzed at AGAT Laboratories in Calgary, an independent ISO 17025 and ISO 9001 certified facility. Samples are dried, crushed to 70% passing 2 mm, split to obtain a 250 g representative portion, and pulverized to 85% passing 75 µm. Gold, platinum, and palladium are assayed by 30-50 g fire assay with ICP-OES finish. Multi-element analyses (up to 48 elements) are performed by four-acid digestion with ICP-OES/MS, with ore-grade assays applied where required. Selected samples are further analyzed for whole-rock oxides using lithium borate fusion with ICP-OES, and Loss on Ignition is determined separately. Routine quality assurance protocols include insertion of blanks, duplicates, and certified reference materials, ensuring accuracy and reliability of results.Doubleview maintains a website at www.doubleview.ca.Qualified Persons:Erik Ostensoe, P. Geo., a consulting geologist, and Doubleview's Qualified Person with respect to the Hat Project as defined by National Instrument 43-101 Standards of Disclosure for Mineral Projects, has reviewed, and approved the technical contents of this news release. He is not independent of Doubleview as he is a shareholder in the company.About Doubleview Gold CorpDoubleview Gold Corp. is mineral resource exploration and development company headquartered in Vancouver, British Columbia, Canada. It is publicly traded on the TSX-Venture Exchange (TSXV: DBG), (OTCQB: DBLVF), (WKN: LA1W038), and (FSE: 1D4). Doubleview focuses on identifying, acquiring, and financing precious and base metal exploration projects across North America, with a strong emphasis on British Columbia. The company enhances shareholder value through the acquisition and exploration of high-quality gold, copper, cobalt, scandium, and silver projects-collectively critical minerals utilizing cutting-edge exploration techniques.Doubleview's success is deeply rooted in the unwavering support of its long-term shareholders, supporters, and institutional investors. Their ongoing commitment has been instrumental in advancing the company's strategic initiatives. Doubleview looks forward to further collaborative growth and development and continues to welcome active participation from its valued stakeholders as the company expands its portfolio and strengthens its position in the critical minerals sector.On behalf of the Board of Directors,Farshad Shirvani, President & Chief Executive OfficerFor further information please contact:Doubleview Gold Corp Vancouver, BC Farshad Shirvani President & CEO T: (604) 678-9587 E: corporate@doubleview.caNEITHER TSX VENTURE EXCHANGE NOR ITS REGULATION SERVICES PROVIDER (AS THAT TERM IS DEFINED IN THE POLICIES OF THE TSX VENTURE EXCHANGE) ACCEPTS RESPONSIBILITY FOR THE ADEQUACY OR ACCURACY OF THIS RELEASE.Forward-Looking InformationCertain of the statements made and information contained herein may constitute "forward-looking information" within the meaning of applicable Canadian securities laws. Forward-looking statements in this news release include, but are not limited to, statements regarding: the interpretation of drill results; the potential extension of mineralization; the identification and significance of the far east mineralized zone; the potential incorporation of drill holes H102 to H108 into future geological models, Mineral Resource Estimates, Preliminary Economic Assessments or other economic studies; the potential for future conversion of Mineral Resources into higher confidence categories; future drilling plans; future exploration programs; the potential economic significance of scandium, cobalt, copper, gold and silver mineralization; and the continued advancement of the Hat Project.Forward-looking statements are based on assumptions that management considers reasonable at the time they are made, including assumptions regarding geological continuity, future exploration results, metallurgical recoveries, metal prices, availability of financing, regulatory approvals, access to the property, and the Company's ability to complete future technical studies. These statements involve known and unknown risks, uncertainties and other factors that may cause actual results to differ materially from those projected. Such risks include, but are not limited to: risks associated with mineral exploration and development; uncertainty of geological interpretation; uncertainty of Mineral Resource estimation; volatility in metal prices; metallurgical and processing risks; permitting and environmental risks; title and access risks; financing risks; equipment availability; First Nations consultation and engagement; and other risks disclosed in the Company's public filings.Except as required by applicable securities legislation, the Company undertakes no obligation to publicly update or revise forward-looking information, whether as a result of new information, future events or otherwise.To view the source version of this press release, please visit https://www.newsfilecorp.com/release/300676 Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

HONG KONG, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Everest Medicines today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. (“Vcare”), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.This collaboration strengthens the Company’s cardiovascular portfolio and highlights Everest’s continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.“This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region,” said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. “Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest’s cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel’s development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients.”"As our novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel’s global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large."As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.Of note, the addition of Sumecigrel further enriches Everest Medicines’ cardiovascular portfolio. As the Company continues to expand its presence in the CKM (cardiovascular, kidney and metabolic) disease space, Sumecigrel is expected to strengthen its cardiovascular product portfolio and generate synergies with existing products and pipeline assets, further deepening the Company’s presence in related therapeutic areas.From a strategic perspective, this collaboration represents another important step in Everest Medicines’ ongoing efforts to deepen its presence across the Asia-Pacific region. Notably, the Company has continued to advance strategic partnerships and resource integration across the region. Through its collaboration with Mabworks, Everest secured the commercialization rights to Bejescin®, a third-generation anti-CD20 therapy, in multiple Asia-Pacific markets, further strengthening its portfolio in nephrology and autoimmune diseases. Industry observers believe that the licensing of Sumecigrel reflects Everest Medicines’ continued commitment to the Asia-Pacific market and its strategy of accelerating the regional development and commercialization of innovative therapies. As its regional product portfolio and operating capabilities continue to expand, Everest Medicines is well positioned to further leverage its integrated biopharmaceutical platform and accelerate the value realization of innovative therapies across the Asia-Pacific region. Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com

SHANGHAI, Jun 9, 2026 - (ACN Newswire via SeaPRwire.com) - Hua Medicine ("the Company", stock code: 2552.HK) presented a series of breakthrough research findings on dorzagliatin (Trade name: HuaTangNing, Trade name in Hong Kong: MYHOMSIS(R)), the world’s first-in-class glucokinase activator (GKA), at the 86th Scientific Sessions of the American Diabetes Association (ADA). Through oral and poster presentations that demonstrated the breadth and depth of its science, the Company showcased data from its Metabolic Homeostasis Technology Platform, spanning combination therapies, large-scale real-world outcomes, AI-powered precision medicine, and personalized care tools.Collectively, the presentations continued to demonstrate the significance of dorzagliatin’s mechanism of action – restoring glucose homeostasis at its root cause – and its therapeutic potential across a spectrum of complex metabolic diseases including Type 2 diabetes (T2D), Metabolic Dysfunction-Associated Steatotic Liver Disease (MASLD), obesity, and Maturity-Onset Diabetes of the Young Type 2 (MODY2).The new research findings strengthen Hua Medicine’s position as a global leader in glucose homeostasis research.I. Leveraging Metabolic Homeostasis Platform to Expand Therapeutic Landscape for Metabolic DiseasesDorzagliatin targets glucokinase (GK), the body’s fundamental glucose sensor, by repairing impaired GK function and expression in patients with Type 2 diabetes to enhance glucose sensitivity. Through coordinated multi-organ regulation across the pancreas, liver, and intestines, dorzagliatin fundamentally restores glucose homeostasis and addresses a broad spectrum of metabolic disorders.Building on this unique mechanism, Hua Medicine presented three combination therapy studies in animal models of metabolic disorder at ADA 2026. The data demonstrate that dorzagliatin acts synergistically with oral small molecule GLP-1 receptor agonists, THR-β agonists, and pan-PPAR agonists. It delivers benefits well beyond glycemic control, including weight reduction, lipid modulation, uric acid reduction, and improved insulin sensitivity.In an oral presentation, Hua Medicine reported preclinical findings evaluating dorzagliatin in combination with the oral small molecule GLP-1 receptor agonist orforglipron. In a significant scientific first, this study demonstrated synergies between a GKA and a small molecule GLP-1RA in animal models, providing a mechanistic and clinical rationale for an oral combination regime that pairs homeostasis restoration with incretin activation. Taken together, the dose-sparing effect, where low-dose combinations achieved comparable efficacy to high-dose monotherapy, addresses one of the most common barriers to GLP-1RA adherence in clinical practice: gastrointestinal tolerability.The study used diet-induced obese (DIO) human GLP-1R transgenic mice, which recapitulate human obesity-associated Type 2 diabetes. The 4-week once-daily oral treatment systematically evaluated monotherapy and combination therapy across key efficacy and safety parameters, including glycemic control, insulin secretion, body weight and lipid profiles.In this model, dorzagliatin repairs GK function across the pancreas, liver, and intestines to restore glucose homeostasis, enhance glucose-stimulated insulin secretion (GSIS), and promote endogenous GLP-1 secretion.Orforglipron directly activates GLP-1 receptors to induce robust weight loss, glycemic control, and lipid improvement; although it also carries the risk of adverse gastrointestinal (GI) events.Synergistic Glycemic Control: Combination therapy produced superior glucose-lowering effects versus monotherapy and enabled dose sparing potential, with low-dose combinations achieving efficacy comparable to high-dose monotherapy. Orforglipron amplified dorzagliatin-mediated improvements in β-cell function and hepatic glucose metabolism.Enhanced β-Cell Function: Dorzagliatin improves the β-cell function of DIO mice, and combined treatment synergistically boosted insulin secretion and sensitivity for better glycemic control and β-cell protection.Preserved Weight and Lipid Benefits: The combination fully retained orforglipron-induced weight reduction and lipid-lowering effects.Favorable Safety and Tolerability: The combination was well tolerated with no new safety signals. Dose sparing markedly reduced common GLP-1RA-related GI side effects such as nausea and vomiting, improving long-term adherence.Together, these complementary mechanisms across glycemic control, weight loss, and lipid improvement, position the potential combination as a highly effective, well-tolerated, and differentiated oral option for T2D patients with obesity. Hua Medicine plans to advance clinical studies to evaluate efficacy, safety, optimal dosing, and target patient populations most likely to benefit.Hua Medicine also presented the findings of two additional combination therapy studies in poster presentations:1.Dorzagliatin + Resmetirom (THR-β Agonist): In DIO mice with MASLD, the combination synergistically improved systemic metabolism and exerted hepatoprotective effects, optimizing glycemic control, regulating lipids, reducing uric acid, and alleviating hepatic fibrosis. This supports the clinical potential of dorzagliatin for T2D patients with MASLD.2.Dorzagliatin + Chiglitazar (Pan-PPAR Agonist): The combination of dorzagliatin and the pan-PPAR agonist chiglitazar demonstrates significant synergistic metabolic benefits in DIO mice model of MASLD. The glucose-lowering effect is superior to monotherapy. At the same time, it optimizes basal glucose metabolism and improves glucose disposal following glucose challenge. Compared with monotherapy, this combination regimen more effectively improves glucose tolerance, reduces insulin resistance, enhances insulin sensitivity and β-cell function, and elevates high-density lipoprotein cholesterol levels in mice. These findings underscore the potential of this combination to address metabolic dysregulation in MASLD and provide important preclinical support for subsequent clinical research to explore its therapeutic value in the metabolic and liver diseases.Together, these studies demonstrate that dorzagliatin’s core mechanism of restoring metabolic homeostasis operates synergistically with multiple targeted agents, supporting its therapeutic potential in obesity, MASLD, and other metabolic disorders.II. Large-Scale Post-Marketing Real-World Study (BLOOM) Validates Long-Term Efficacy and SafetyAt ADA 2026, Hua Medicine presented further key results from the BLOOM study, a large-scale post-marketing real-world investigation of dorzagliatin in routine clinical settings.BLOOM aims to evaluate the long-term safety and effectiveness of dorzagliatin in a broad, clinically diverse population of people with Type 2 diabetes. The BLOOM study enrolled 2,024 patients with Type 2 diabetes across 80 clinical centers in China (62% male; mean age 55.5 years; mean BMI 25.1 kg/m²; mean diabetes duration 7.9 years; baseline HbA1c 7.8%) with dorzagliatin treatment and follow-up lasting up to 52 weeks. It evaluated long-term safety and effectiveness of dorzagliatin as monotherapy or in combination with other anti-diabetic agents in real clinical settings, including elderly patients, people with renal impairment, and those on complex multiple-drug regimens including insulin. The study results demonstrated that:During the 52-week treatment period, no drug-related serious adverse events (SAEs) or severe hypoglycemia were reported over 52 weeks. Clinically meaningful hypoglycemia remained

KOSICE, SLOVAKIA, June 9, 2026 - (ACN Newswire via SeaPRwire.com) - The original film by Vlado Zelezňák Jr. has achieved remarkable international success. The new Slovak-Japanese animated sci-fi film Angel & Meow celebrated its World Premiere by winning the prestigious Crystal Pine Award. The film proved its quality against an immense global competition of nearly 1,000 entries from 81 countries. This achievement is particularly notable as the film was produced as a fully independent project by the Slovak company GONG Art Company, led by Vlado Zelezňák Sr.The success took place at the 14th International Sound & Film Music Festival (ISFMF) in Varazdin, Croatia, which ranks among the world’s three most significant festivals dedicated to film music and sound. The gala ceremony was held in the magnificent historic setting of the Croatian National Theatre (HNK Varazdin).In the Company of Oscar Winners and Hollywood Stars The winners were selected by a prestigious international jury consisting of elite professionals—recipients and nominees of Oscar, Emmy, BAFTA, Grammy, and César awards. The jury president for this year was the legendary and respected actor Ciarán Hinds. Widely considered one of the most acclaimed actors of his generation, Hinds is known to audiences for global blockbusters such as Game of Thrones, Harry Potter and the Deathly Hallows, the Oscar-winning drama Belfast, and the animated phenomenon Frozen.Slovak creators stood on stage alongside the world’s absolute elite. Other award-winning personalities at this year’s festival included Hollywood actor Simon Pegg (Mission: Impossible, Star Trek), who received a Lifetime Achievement Award, and Oscar-winning sound designer James Mather (Top Gun: Maverick). The Slovak team shared the spotlight with elite sound professionals from the film Sirât, including Yasmina Praderas (Goya winner and Oscar nominee) and Laia Casanovas (European Film Award and Goya winner).Personal Moments from the Festival Stage The heart and engine of the project is Slovak producer, screenwriter, composer, and sound designer Vlado Zelezňák Jr., who accepted the award directly from the festival directors. During the gala, he experienced unforgettable personal encounters with the world’s biggest film stars."When we stood on stage after the announcement, I expressed my appreciation to the jury president, Ciarán Hinds, for his work. I was delighted that he already recognized our film—he responded immediately with a wide smile by singing the title of our project. It was a pleasant and spontaneous experience," recalls Vlado Zelezňák Jr.The meeting with Hollywood actor Simon Pegg was equally emotional. "I spoke with Simon on the day of the World Premiere, where I had the opportunity to introduce our film to him personally. When we met again on stage the next day during the awards ceremony, it was great to see that he was familiar with Angel & Meowand congratulated me with a smile again. These moments are a huge encouragement for my future work," adds the Slovak creator.The entire event was managed by the festival founders. The gala was hosted by Artistic Director Ozren K. Glaser, who publicly congratulated Vlado Zelezňák Jr. on stage, while Executive Director Marijana Glaser ceremoniously presented the Crystal Pine Award. "Our huge thanks go to the three main organizers from the Glaser family—Marijana, Ozren, and producer Zeljko Glaser. I would like to express my appreciation for their excellent, professional organization and for building a festival of a truly Hollywood standard, where one felt like they were at the Oscars from the very first moment," concludes Vlado Zelezňák Jr.A World Premiere of Visual Poetry Before an Elite Audience The World Premiere of Angel & Meow, held on May 22 at CineStar Varazdin, played to a fully packed theater. The audience consisted of an elite group of nominated composers, sound designers, and filmmakers from around the world. The premiere was attended in person by living legends of the film industry, such as Oscar-winning sound mixer Mark Ulano (Titanic, Inglourious Basterds), as well as singer and producer Kathy Kelly from the legendary group The Kelly Family.In addition to high-quality animation and visuals, the international jury praised the film’s powerful sound design, original score, and the overall story, all created by Vlado Zelezňák Jr. The visual and animation components were crafted by a top-tier Japanese team in Tokyo, led by director and lead animator Clemhyn Escosora from Adarnia studio (a subsidiary of Fuji Corp.).Global Sound Design and a Soundtrack as a Narrator Since the story relies on the pure power of image and sound, the meticulously designed sound and film music step into the spotlight, taking on the role of the primary narrator alongside the animation. The resulting soundtrack is exceptionally rich, varied, and intense."The sound design was created all over the world. While atmospheric sounds were recorded directly on the streets and coast of Cannes, the orchestral and electronic music was composed in studios in Slovakia. To achieve absolute authenticity, we recorded live animals and constantly experimented with sound," explains Vlado Zelezňák Jr. Over the 15-minute runtime, the viewer experiences diverse musical landscapes—from massive orchestral passages and intimate piano and guitar moments to pure sci-fi sounds of analog Moog synthesizers and wind instruments.Sound in the Hands of a Living Legend The final sound mastering was handled in the USA by an absolute legend in the field—Vlado Meller, in his prestigious American studio. Throughout his rich career, he has collaborated with icons such as Céline Dion, Andrea Bocelli, and the Red Hot Chili Peppers. Meller recently exclusively finished Dolby Atmos mastering for Michael Jackson’s legendary albums for Sony USA, released in conjunction with the recently unveiled biographical film hit Michael.Angel & Meow has shown from the very start that independent Slovak production from the GONG Art Company workshop, combined with an original script, film music, and sound design, can successfully stand its ground on the international stage against the world's biggest productions.About GONG Art Company30 Years of Creativity and Innovation GONG Art Company is an established pillar of the Slovak audiovisual scene with a nearly 30-year history. The company is renowned for its long-standing technological and creative co-production work with Slovak National Television and Radio, providing comprehensive music production for iconic projects such as Hviezdička and Zlatá brána. The company has been awarded multiple Gold and Platinum records for its music production and children's audio titles.Today, GONG operates as a modern production house focused on international film co-productions. The company manages its own film projects, with in-house recording studios dedicated to film scoring and sound design. This infrastructure allows for simultaneous production across multiple works—while the soundtrack for Angel & Meow was being composed in one studio, another was handling sound post-production for the documentary Man from the Mountain, which is also heading to international film festivals this year.GONG is also the founder of the global platform FMC (Film Music Contest & Festival), which connects elites from Hollywood and Netflix with global talent. The team regularly participates in key industry markets such as Cannes (Marché du Film), Annecy (MIFA), and Berlinale (EFM), building on a tradition of high-quality original work with the ambition to succeed in the global market.More information: www.angelandmeow.com Media Contact: Mgr. Vlado Zelezňák JR. Phone: +421 911 789 888 Email: press@angelandmeow.com Facebook: https://www.facebook.com/angelandmeowmovie/ Instagram: https://www.instagram.com/angelandmeowmovie/ Copyright 2026 ACN Newswire via SeaPRwire.com. All rights reserved. www.acnnewswire.com